Assessing cardiovascular disease risk in patients with type 2 diabetes using advanced computational tools
ASCVD risk assessment in T2DM facilitated by novel computational immunology programs
This study is looking at how type 2 diabetes can increase the risk of heart disease by examining the role of certain immune cells, and it aims to find better ways to predict and manage this risk for people with diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-10993204 on NIH RePORTER |
What this research studies
This research investigates the increased risk of atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes mellitus (T2DM). It aims to develop and utilize novel computational immunology programs to better predict ASCVD risk by analyzing the behavior of immune cells, particularly monocytes, in T2DM patients. The study will explore how these immune cells contribute to the development of harmful foam cells that elevate cardiovascular risk. By improving risk assessment, the research seeks to identify more effective strategies for managing and mitigating ASCVD in this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes mellitus who are at risk for atherosclerotic cardiovascular disease.
Not a fit: Patients without a diagnosis of type 2 diabetes or those who do not have cardiovascular disease risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate risk assessments and targeted interventions for patients with type 2 diabetes, potentially reducing their risk of cardiovascular disease.
How similar studies have performed: Previous research has shown promise in using computational tools to assess cardiovascular risk, but this specific approach focusing on immune cell behavior in T2DM is relatively novel.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Zhou, Beiyan — University of Connecticut Sch of Med/dnt
- Study coordinator: Zhou, Beiyan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.